•This study identified four compounds, two of these FDA approved drugs, that target the mutational hot spot K700E and functional amino acid residue R630 that may have the potential to modulate SF3B1 activity in myelodysplastic syndrome (MDS) and other neoplasms linked to SF3B1 splicing control. This evidence concerns the gene SF3B1 and neoplasm.